258 related articles for article (PubMed ID: 26211512)
1. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
2. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Simkens LH; Koopman M; Mol L; Veldhuis GJ; Ten Bokkel Huinink D; Muller EW; Derleyn VA; Teerenstra S; Punt CJ
Eur J Cancer; 2011 Nov; 47(17):2560-7. PubMed ID: 21803570
[TBL] [Abstract][Full Text] [Related]
3. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
4. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Aparicio T; Ducreux M; Faroux R; Barbier E; Manfredi S; Lecomte T; Etienne PL; Bedenne L; Bennouna J; Phelip JM; François E; Michel P; Legoux JL; Gasmi M; Breysacher G; Rougier P; De Gramont A; Lepage C; Bouché O; Seitz JF;
Eur J Cancer; 2018 Jul; 98():1-9. PubMed ID: 29807237
[TBL] [Abstract][Full Text] [Related]
5. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
6. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
[TBL] [Abstract][Full Text] [Related]
7. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Faruk Aykan N; Yildiz I; Sen F; Kilic L; Keskin S; Ciftci R; Karabulut S; Sakar B; Disci R
Med Oncol; 2013; 30(3):679. PubMed ID: 23921648
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Moehler M; Thomaidis T; Zeifri C; Barhoom T; Marquardt J; Ploch P; Schattenberg J; Maderer A; Schimanski CC; Weinmann A; Woerns MA; Kranich AL; Warnecke JM; Galle PR
J Cancer Res Clin Oncol; 2015 Mar; 141(3):515-22. PubMed ID: 25230900
[TBL] [Abstract][Full Text] [Related]
9. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
[TBL] [Abstract][Full Text] [Related]
10. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
[TBL] [Abstract][Full Text] [Related]
11. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
[TBL] [Abstract][Full Text] [Related]
12. Do acute hospitalised patients in Australia have a different body mass index to the general Australian population: a point prevalence study?
Dennis DM; Carter V; Trevenen M; Tyler J; Perrella L; Lori E; Cooper I
Aust Health Rev; 2018 Apr; 42(2):121-129. PubMed ID: 28225703
[TBL] [Abstract][Full Text] [Related]
13. A paradox between preoperative overweight/obesity and change in weight during postoperative chemotherapy and its relationship to survival in stage Ⅱ and Ⅲ colorectal cancer patients.
Hu C; Zhang Q; Jin X; Zhang L; Zhang Y; Zhu Q; Tang M; Lyv G; Shi H
Clin Nutr; 2021 Apr; 40(4):2410-2419. PubMed ID: 33183882
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
15. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
16. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
[TBL] [Abstract][Full Text] [Related]
17. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
18. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.
Gennari A; Nanni O; Puntoni M; DeCensi A; Scarpi E; Conte P; Antonucci G; Amadori D; Bruzzi P
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1862-7. PubMed ID: 23945199
[TBL] [Abstract][Full Text] [Related]
20. Obesity is an independent prognostic variable in colon cancer survivors.
Sinicrope FA; Foster NR; Sargent DJ; O'Connell MJ; Rankin C
Clin Cancer Res; 2010 Mar; 16(6):1884-93. PubMed ID: 20215553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]